At a glance
ClinicalIndex Comparison RecordN/ACompleted· 223 enrolled
Drug / intervention
sunitinibdrug
Likely dose
Not stated in record
Key inclusion· 1
- ✓Must have completed treatment in one of the specified prior sunitinib studies (A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126, A6181170, or other Pfizer-sponsored sunitinib studies).
Key exclusion· 0
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
In Brief
A clinical study evaluating sunitinib for Metastatic Breast Cancer and 11 related conditions. Completed, enrolled 223 participants across 113 sites in 17 countries.
Detailed Summary
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor
CountriesArgentina, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Hong Kong, Mexico, Philippines, Singapore, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartJul 2007
Primary CompletionAug 2014
Study CompletionSep 2014
TodayJul 2026
First PostedJan 29, 2007
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 19.4 years ago
Interventions
sunitinibdrug
sunitinib